메뉴 건너뛰기




Volumn 6, Issue 4, 2014, Pages 431-458

Radioimmunotherapy with α-particle-emitting radionuclides

Author keywords

antibody; radioimmunotherapy; radionuclide; targeted therapy; emitter

Indexed keywords

ACTINIUM 225; ANTIBODY CONJUGATE; ASTATINE 211; BISMUTH 212; BISMUTH 213; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LEAD 212; RADIOISOTOPE; RADIUM CHLORIDE RA 223; TERBIUM 149; THORIUM; THORIUM 227; UNCLASSIFIED DRUG;

EID: 84900389533     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.16     Document Type: Article
Times cited : (68)

References (177)
  • 1
    • 84863576788 scopus 로고    scopus 로고
    • An overview of targeted alpha therapy
    • Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 33, 573-590 (2012).
    • (2012) Tumour Biol. , vol.33 , pp. 573-590
    • Kim, Y.S.1    Brechbiel, M.W.2
  • 2
    • 78650719836 scopus 로고    scopus 로고
    • Current concepts and future directions in radioimmunotherapy
    • Lin FI, Iagaru A. Current concepts and future directions in radioimmunotherapy. Curr. Drug Discov. Technol. 7, 253-262 (2010).
    • (2010) Curr. Drug Discov. Technol. , vol.7 , pp. 253-262
    • Lin, F.I.1    Iagaru, A.2
  • 3
    • 78650991430 scopus 로고    scopus 로고
    • Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
    • Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117, 45-52 (2011).
    • (2011) Blood , vol.117 , pp. 45-52
    • Leahy, M.F.1    Turner, J.H.2
  • 4
    • 84867787497 scopus 로고    scopus 로고
    • Radiolabeled antibodies for cancer imaging and therapy
    • Barbet J, Bardi? M, Bourgeois M et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol. Biol. 907, 681-697 (2012).
    • (2012) Methods Mol. Biol. , vol.907 , pp. 681-697
    • Barbet, J.1    Bardi, M.2    Bourgeois, M.3
  • 8
    • 84875948186 scopus 로고    scopus 로고
    • Radioimmunotherapy for peritoneal cancers
    • Seidl C, Essler M. Radioimmunotherapy for peritoneal cancers. Immunotherapy 5, 395-405 (2013).
    • (2013) Immunotherapy , vol.5 , pp. 395-405
    • Seidl, C.1    Essler, M.2
  • 10
    • 76349109469 scopus 로고    scopus 로고
    • Anti-prostatespecific membrane antigen-based radioimmunotherapy for prostate cancer
    • Tagawa ST, Beltran H, Vallabhajosula S et al. Anti-prostatespecific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116 (4 Suppl.), 1075-1083 (2010).
    • (2010) Cancer , vol.116 , Issue.4 SUPPL. , pp. 1075-1083
    • Tagawa, S.T.1    Beltran, H.2    Vallabhajosula, S.3
  • 11
    • 84875965291 scopus 로고    scopus 로고
    • Radioimmunotherapy for hematopoietic cell transplantation
    • Jurcic JG. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy 5, 383-394 (2013).
    • (2013) Immunotherapy , vol.5 , pp. 383-394
    • Jurcic, J.G.1
  • 12
    • 75749110617 scopus 로고    scopus 로고
    • MIRD pamphlet 22 (abridged): Radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy
    • Sgouros G, Roeske JC, McDevitt MR et al. MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311-328 (2010).
    • (2010) J. Nucl. Med. , vol.51 , pp. 311-328
    • Sgouros, G.1    Roeske, J.C.2    McDevitt, M.R.3
  • 14
    • 84900439357 scopus 로고    scopus 로고
    • Zielgerichtete Radionuklidtherapie mit α-Emittern-Grundlagen experimentelle und erste klinische Studien
    • Seidl C, Senekowitsch-Schmidtke R. Zielgerichtete Radionuklidtherapie mit α-Emittern-Grundlagen, experimentelle und erste klinische Studien. Der Nuklearmediziner 31, 81-92 (2008).
    • (2008) Der Nuklearmediziner , vol.31 , pp. 81-92
    • Seidl, C.1    Senekowitsch-Schmidtke, R.2
  • 15
    • 35549000927 scopus 로고    scopus 로고
    • Targeted alpha-therapy: Past, present, future
    • Brechbiel MW. Targeted alpha-therapy: past, present, future? Dalton Trans. 21, 4918-4928 (2007).
    • (2007) Dalton Trans. , vol.21 , pp. 4918-4928
    • Brechbiel, M.W.1
  • 17
    • 84856275035 scopus 로고    scopus 로고
    • Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells
    • Franken NA, Hovingh S, Ten Cate R et al. Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells. Oncol. Rep. 27, 769-774 (2012).
    • (2012) Oncol. Rep. , vol.27 , pp. 769-774
    • Franken, N.A.1    Hovingh, S.2    Ten Cate, R.3
  • 18
    • 84856288224 scopus 로고    scopus 로고
    • H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues
    • Firsanov DV, Solovjeva LV, Svetlova MP. H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues. Clin. Epigenetics 2, 283-297 (2011).
    • (2011) Clin. Epigenetics , vol.2 , pp. 283-297
    • Firsanov, D.V.1    Solovjeva, L.V.2    Svetlova, M.P.3
  • 19
    • 84878410708 scopus 로고    scopus 로고
    • Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation
    • Wulbrand C, Seidl C, Gaertner FC et al. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS ONE 8, e64730 (2013).
    • (2013) PLoS ONE , vol.8
    • Wulbrand, C.1    Seidl, C.2    Gaertner, F.C.3
  • 21
    • 77952095165 scopus 로고    scopus 로고
    • In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin
    • Petrich T, Korkmaz Z, Krull D, Fr?ke C, Meyer GJ, Knapp WH. In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur. J. Nucl. Med. Mol. Imaging 37, 851-861 (2010).
    • (2010) Eur. J. Nucl. Med. Mol. Imaging , vol.37 , pp. 851-861
    • Petrich, T.1    Korkmaz, Z.2    Krull, D.3    Frke, C.4    Meyer, G.J.5    Knapp, W.H.6
  • 22
    • 84878373820 scopus 로고    scopus 로고
    • The repair and signaling responses to DNA double-strand breaks
    • Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv. Genet. 82, 1-45 (2013).
    • (2013) Adv. Genet. , vol.82 , pp. 1-45
    • Goodarzi, A.A.1    Jeggo, P.A.2
  • 23
    • 84879953282 scopus 로고    scopus 로고
    • DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy
    • Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front. Oncol. 3, 113 (2013).
    • (2013) Front. Oncol. , vol.3 , pp. 113
    • Mladenov, E.1    Magin, S.2    Soni, A.3    Iliakis, G.4
  • 24
    • 84875198804 scopus 로고    scopus 로고
    • Chromatin remodeling at DNA double-strand breaks
    • Price BD, D'Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell 152, 1344-1354 (2013).
    • (2013) Cell , vol.152 , pp. 1344-1354
    • Price, B.D.1    D'Andrea, A.D.2
  • 25
    • 84876274744 scopus 로고    scopus 로고
    • Histone modifications and DNA double-strand break repair after exposure to ionizing radiations
    • Hunt CR, Ramnarain D, Horikoshi N et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat. Res. 179, 383-392 (2013).
    • (2013) Radiat. Res. , vol.179 , pp. 383-392
    • Hunt, C.R.1    Ramnarain, D.2    Horikoshi, N.3
  • 27
    • 74149087930 scopus 로고    scopus 로고
    • Differential gene expression triggered by highly cytotoxic alpha-emitterimmunoconjugates in gastric cancer cells
    • Seidl C, Port M, Apostolidis C et al. Differential gene expression triggered by highly cytotoxic alpha-emitterimmunoconjugates in gastric cancer cells. Invest. New Drugs 28, 49-60 (2010).
    • (2010) Invest. New Drugs , vol.28 , pp. 49-60
    • Seidl, C.1    Port, M.2    Apostolidis, C.3
  • 28
    • 84875849377 scopus 로고    scopus 로고
    • Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation
    • Danielsson A, Claesson K, Parris TZ et al. Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation. Int. J. Radiat. Biol. 89, 250-258 (2013).
    • (2013) Int. J. Radiat. Biol. , vol.89 , pp. 250-258
    • Danielsson, A.1    Claesson, K.2    Parris, T.Z.3
  • 29
    • 84865620494 scopus 로고    scopus 로고
    • Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography
    • Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat. Res. 751, 158-246 (2012).
    • (2012) Mutat. Res. , vol.751 , pp. 158-246
    • Thompson, L.H.1
  • 30
    • 84873350765 scopus 로고    scopus 로고
    • Molecular pathways: Targeted α-particle radiation therapy
    • Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin. Cancer Res. 19, 530-537 (2013).
    • (2013) Clin. Cancer Res. , vol.19 , pp. 530-537
    • Baidoo, K.E.1    Yong, K.2    Brechbiel, M.W.3
  • 31
    • 80052209707 scopus 로고    scopus 로고
    • Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates
    • Dahle J, Abbas N, Bruland ?S, Larsen RH. Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates. Curr. Radiopharm. 4, 321-328 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 321-328
    • Dahle, J.1    Abbas, N.2    Bruland, S.3    Larsen, R.H.4
  • 33
    • 0037464557 scopus 로고    scopus 로고
    • Experimental detection of α-particles from the radioactive decay of natural bismuth
    • DOI 10.1038/nature01541
    • de Marcillac P, Coron N, Dambier G, Leblanc J, Moalic JP. Experimental detection of alpha-particles from the radioactive decay of natural bismuth. Nature 422, 876-878 (2003). (Pubitemid 36520036)
    • (2003) Nature , vol.422 , Issue.6934 , pp. 876-878
    • De Marcillac, P.1    Coron, N.2    Dambier, G.3    Leblanc, J.4    Moalic, J.-P.5
  • 34
    • 26444597027 scopus 로고    scopus 로고
    • Production of Ac-225 from Th-229 for targeted α therapy
    • DOI 10.1021/ac0580114
    • Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal. Chem. 77, 6288-6291(2005). (Pubitemid 41436964)
    • (2005) Analytical Chemistry , vol.77 , Issue.19 , pp. 6288-6291
    • Apostolidis, C.1    Molinet, R.2    Rasmussen, G.3    Morgenstern, A.4
  • 35
    • 84863557811 scopus 로고    scopus 로고
    • Bismuth-213 and actinium-225-generator performance and evolving therapeutic applications of two generator-derived alphaemitting radioisotopes
    • Morgenstern A, Bruchertseifer F, Apostolidis C. Bismuth-213 and actinium-225-generator performance and evolving therapeutic applications of two generator-derived alphaemitting radioisotopes. Curr. Radiopharm. 5, 221-227 (2012).
    • (2012) Curr. Radiopharm. , vol.5 , pp. 221-227
    • Morgenstern, A.1    Bruchertseifer, F.2    Apostolidis, C.3
  • 36
    • 79551705078 scopus 로고    scopus 로고
    • Renal ptauke of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
    • Schwartz J, Jaggi JS, O'Donoghue JA et al. Renal ptauke of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys. Med. Biol. 56, 721-733 (2011).
    • (2011) Phys. Med. Biol. , vol.56 , pp. 721-733
    • Schwartz, J.1    Jaggi, J.S.2    O'Donoghue, J.A.3
  • 37
    • 45749101319 scopus 로고    scopus 로고
    • 225Ac in rigid liposomes for potential targeted therapy of micrometastases
    • DOI 10.1021/bc700440a
    • Chang MY, Seideman J, Sofou S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug. Chem. 19, 1274-1282 (2008). (Pubitemid 351874951)
    • (2008) Bioconjugate Chemistry , vol.19 , Issue.6 , pp. 1274-1282
    • Change, M.-Y.1    Seideman, J.2    Sofou, S.3
  • 38
    • 84872565992 scopus 로고    scopus 로고
    • Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy
    • McLaughlin MF, Woodward J, Boll RA et al. Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS ONE 8, e54531 (2013).
    • (2013) PLoS ONE , vol.8
    • McLaughlin, M.F.1    Woodward, J.2    Boll, R.A.3
  • 39
    • 79959430516 scopus 로고    scopus 로고
    • Astatine-211: Production and availability
    • Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr. Radiopharm. 4, 177-185 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 177-185
    • Zalutsky, M.R.1    Pruszynski, M.2
  • 40
    • 84872176323 scopus 로고    scopus 로고
    • Production of [211) At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy
    • Gu?ard F, Gestin JF, Brechbiel MW. Production of [(211) At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother. Radiopharm. 28, 1-20 (2013).
    • (2013) Cancer Biother. Radiopharm , vol.28 , pp. 1-20
    • Guard, F.1    Gestin, J.F.2    Brechbiel, M.W.3
  • 43
    • 84863382114 scopus 로고    scopus 로고
    • Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with A maleimido-closo-decaborate(2-) Reagent Via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations Than the Same Antibody Conjugated with An Isothiocyanato-closodecaborate( 2-) Reagent Via Lysine Amines
    • Wilbur DS, Chyan MK, Nakamae H et al. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo- decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato- closodecaborate( 2-) reagent via lysine amines. Bioconjug. Chem. 23, 409-420 (2012).
    • (2012) Bioconjug. Chem. , vol.23 , pp. 409-420
    • Wilbur, D.S.1    Chyan, M.K.2    Nakamae, H.3
  • 44
    • 79958212847 scopus 로고    scopus 로고
    • Towards translation of 212Pb as a clinical therapeutic; Getting the lead
    • Yong K, Brechbiel MW. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 40, 6068-6076 (2011).
    • (2011) Dalton Trans , vol.40 , pp. 6068-6076
    • Yong, K.1    Brechbiel, M.W.2
  • 45
    • 84878174664 scopus 로고    scopus 로고
    • Methodology for labeling proteins and peptides with lead-212 (212Pb)
    • Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl. Med. Biol. 40, 592-599 (2013).
    • (2013) Nucl. Med. Biol. , vol.40 , pp. 592-599
    • Baidoo, K.E.1    Milenic, D.E.2    Brechbiel, M.W.3
  • 46
    • 84891676245 scopus 로고    scopus 로고
    • Half-lifes of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series
    • Suliman G, Pomm?S, Marouli M et al. Half-lifes of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series. Appl. Radiat. Isot. 77, 32-37 (2013).
    • (2013) Appl. Radiat. Isot. , vol.77 , pp. 32-37
    • Suliman, G.1    Pomms2    Marouli, M.3
  • 47
    • 1842850605 scopus 로고    scopus 로고
    • Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides
    • DOI 10.1016/j.nucmedbio.2003.11.004, PII S0969805103002117
    • Henriksen G, Schoultz BW, Michaelsen TE, Bruland ?S, Larsen RH. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl. Med. Biol. 31, 441-449 (2004). (Pubitemid 38490743)
    • (2004) Nuclear Medicine and Biology , vol.31 , Issue.4 , pp. 441-449
    • Henriksen, G.1    Schoultz, B.W.2    Michaelsen, T.E.3    Bruland, O.S.4    Larsen, R.H.5
  • 48
    • 84881630281 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castrationresistant metastatic prostate cancer
    • Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castrationresistant metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 40, 1384-1393 (2013).
    • (2013) Eur. J. Nucl. Med. Mol. Imaging , vol.40 , pp. 1384-1393
    • Carrasquillo, J.A.1    O'Donoghue, J.A.2    Pandit-Taskar, N.3
  • 49
    • 84872507131 scopus 로고    scopus 로고
    • Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
    • Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag. Res. 5, 1-14 (2013).
    • (2013) Cancer Manag. Res. , vol.5 , pp. 1-14
    • Harrison, M.R.1    Wong, T.Z.2    Armstrong, A.J.3    George, D.J.4
  • 50
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
    • (2013) N. Engl. J. Med. , vol.369 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 52
    • 84864121928 scopus 로고    scopus 로고
    • Measurement of the 226Th and 222Ra half-lives
    • Pomm?S, Suliman G, Marouli M et al. Measurement of the 226Th and 222Ra half-lives. Appl. Radiat. Isot. 70, 1913-1918 (2012).
    • (2012) Appl. Radiat. Isot. , vol.70 , pp. 1913-1918
    • Pomm, S.1    Suliman, G.2    Marouli, M.3
  • 54
    • 56449102606 scopus 로고    scopus 로고
    • Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa
    • Morgenstern A, Lebeda O, Stursa J et al. Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa. Anal. Chem. 80, 8763-8770 (2008).
    • (2008) Anal. Chem. , vol.80 , pp. 8763-8770
    • Morgenstern, A.1    Lebeda, O.2    Stursa, J.3
  • 55
    • 84900427069 scopus 로고    scopus 로고
    • Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb
    • Toronto, Canada,13-17 June
    • Pfost B, Morgenstern A, Seidl C et al. Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb. Presented at: the 6th Symposium on Alpha-Emitting Radionuclides in Therapy. Toronto, Canada, 13-17 June 2009.
    • (2009) 6th Symposium on Alpha-Emitting Radionuclides in Therapy
    • Pfost, B.1    Morgenstern, A.2    Seidl, C.3
  • 56
    • 33644942120 scopus 로고    scopus 로고
    • Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate alphaparticle radioimmunotherapy
    • Dahle J, Borrebaek J, Melhus KB et al. Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate alphaparticle radioimmunotherapy. Nucl. Med. Biol. 33, 271-279 (2006).
    • (2006) Nucl. Med. Biol. , vol.33 , pp. 271-279
    • Dahle, J.1    Borrebaek, J.2    Melhus, K.B.3
  • 58
    • 80052230219 scopus 로고    scopus 로고
    • Actinium-225 in targeted alpha-particle therapeutic applications
    • Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr. Radiopharm. 4, 306-320 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 306-320
    • Scheinberg, D.A.1    McDevitt, M.R.2
  • 61
    • 6044248953 scopus 로고    scopus 로고
    • Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of α-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    • DOI 10.1158/1078-0432.CCR-04-0859
    • Miederer M, McDevitt MR, Borchardt P et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin. Cancer Res. 10, 6985-6992 (2004). (Pubitemid 39383050)
    • (2004) Clinical Cancer Research , vol.10 , Issue.20 , pp. 6985-6992
    • Miederer, M.1    McDevitt, M.R.2    Borchardt, P.3    Bergman, I.4    Kramer, K.5    Cheung, N.-K.V.6    Scheinberg, D.A.7
  • 62
    • 84891702990 scopus 로고    scopus 로고
    • Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization
    • Jaggi JS, Henke E, Seshan SV et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE 2, e267 (2007).
    • (2007) PLoS ONE , vol.2
    • Jaggi, J.S.1    Henke, E.2    Seshan, S.V.3
  • 63
    • 78549248213 scopus 로고    scopus 로고
    • Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors
    • Escorcia FE, Henke E, McDevitt MR et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 70, 9277-9286 (2010).
    • (2010) Cancer Res. , vol.70 , pp. 9277-9286
    • Escorcia, F.E.1    Henke, E.2    McDevitt, M.R.3
  • 64
    • 79952115407 scopus 로고    scopus 로고
    • Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
    • Ruggiero A, Villa CH, Holland JP et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomedicine 5, 783-802 (2010).
    • (2010) Int. J. Nanomedicine , vol.5 , pp. 783-802
    • Ruggiero, A.1    Villa, C.H.2    Holland, J.P.3
  • 65
    • 77955459129 scopus 로고    scopus 로고
    • Paradoxical glomerular filtration of carbon nanotubes
    • Ruggiero A, Villa CH, Bander E et al. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl Acad. Sci. USA 107, 12369-12374 (2010).
    • (2010) Proc. Natl Acad. Sci. USA , vol.107 , pp. 12369-12374
    • Ruggiero, A.1    Villa, C.H.2    Bander, E.3
  • 66
    • 71549168624 scopus 로고    scopus 로고
    • Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac comparing efficacy with 213Bi and 90Y
    • Song H, Hobbs RF, Vajravelu R et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac. comparing efficacy with 213Bi and 90Y. Cancer Res. 69, 8941-8948 (2009).
    • (2009) Cancer Res. , vol.69 , pp. 8941-8948
    • Song, H.1    Hobbs, R.F.2    Vajravelu, R.3
  • 68
    • 80052242015 scopus 로고    scopus 로고
    • Applications of 211At and 223Ra in targeted alpha-particle radiotherapy
    • Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr. Radiopharm. 4, 283-294 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 283-294
    • Vaidyanathan, G.1    Zalutsky, M.R.2
  • 70
    • 33646061955 scopus 로고    scopus 로고
    • In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction
    • Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl. Med. Biol. 33, 333-347 (2006).
    • (2006) Nucl. Med. Biol. , vol.33 , pp. 333-347
    • Akabani, G.1    Carlin, S.2    Welsh, P.3    Zalutsky, M.R.4
  • 71
    • 84864066701 scopus 로고    scopus 로고
    • Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with 211At
    • Cederkrantz E, Angenete E, B?k T et al. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with 211At. Cancer Biother. Radiopharm. 27, 353-364 (2012).
    • (2012) Cancer Biother. Radiopharm. , vol.27 , pp. 353-364
    • Cederkrantz, E.1    Angenete, E.2    Bk, T.3
  • 72
    • 67651177582 scopus 로고    scopus 로고
    • Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting 211At-labeled trastuzumab
    • Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting 211At-labeled trastuzumab. Nucl. Med. Biol. 36, 659-669 (2009).
    • (2009) Nucl. Med. Biol. , vol.36 , pp. 659-669
    • Boskovitz, A.1    McLendon, R.E.2    Okamura, T.3    Sampson, J.H.4    Bigner, D.D.5    Zalutsky, M.R.6
  • 74
    • 34249889331 scopus 로고    scopus 로고
    • Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma
    • DOI 10.1097/MLG.0b013e31804b1a6d
    • Cheng J, Ekberg T, Engstr? M et al. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. Laryngoscope 117, 1013-1018 (2007). (Pubitemid 46869837)
    • (2007) Laryngoscope , vol.117 , Issue.6 , pp. 1013-1018
    • Cheng, J.1    Ekberg, T.2    Engstrom, M.3    Nestor, M.4    Jensen, H.J.5    Tolmachev, V.6    Anniko, M.7
  • 81
    • 79959191869 scopus 로고    scopus 로고
    • Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice
    • Elgqvist J, Andersson H, Jensen H et al. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice. J. Oncol. 2010, 394913 (2010).
    • (2010) J. Oncol. , vol.2010 , pp. 394913
    • Elgqvist, J.1    Andersson, H.2    Jensen, H.3
  • 83
    • 69249107784 scopus 로고    scopus 로고
    • Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities
    • Elgqvist J, Andersson H, Haglund E et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother. Radiopharm. 24, 509-513 (2009).
    • (2009) Cancer Biother. Radiopharm. , vol.24 , pp. 509-513
    • Elgqvist, J.1    Andersson, H.2    Haglund, E.3
  • 84
    • 84855322802 scopus 로고    scopus 로고
    • Comparison of therapeutic efficacy and biodistribution of 213Bi-and 211Atlabeled monoclonal antibody MX35 in an ovarian cancer model
    • Gustafsson AM, B?k T, Elgqvist J et al. Comparison of therapeutic efficacy and biodistribution of 213Bi-and 211Atlabeled monoclonal antibody MX35 in an ovarian cancer model. Nucl. Med. Biol. 39, 15-22 (2012).
    • (2012) Nucl. Med. Biol. , vol.39 , pp. 15-22
    • Gustafsson, A.M.1    Bk, T.2    Elgqvist, J.3
  • 85
    • 84874755179 scopus 로고    scopus 로고
    • Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model
    • Frost SH, B?k T, Chouin N et al. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother. Radiopharm. 28, 108-114 (2013).
    • (2013) Cancer Biother. Radiopharm. , vol.28 , pp. 108-114
    • Frost, S.H.1    Bk, T.2    Chouin, N.3
  • 86
    • 84881422571 scopus 로고    scopus 로고
    • Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique
    • Chouin N, Lindegren S, Frost SH et al. Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique. J. Nucl. Med. 54, 1347-1353 (2013).
    • (2013) J. Nucl. Med. , vol.54 , pp. 1347-1353
    • Chouin, N.1    Lindegren, S.2    Frost, S.H.3
  • 87
    • 84863012882 scopus 로고    scopus 로고
    • Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation
    • Chen Y, Kornblit B, Hamlin DK et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 119, 1130-1138 (2012).
    • (2012) Blood , vol.119 , pp. 1130-1138
    • Chen, Y.1    Kornblit, B.2    Hamlin, D.K.3
  • 88
    • 84879712790 scopus 로고    scopus 로고
    • Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
    • Orozco JJ, B?k T, Kenoyer A et al. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood 121, 3759-3767 (2013).
    • (2013) Blood , vol.121 , pp. 3759-3767
    • Orozco, J.J.1    Bk, T.2    Kenoyer, A.3
  • 89
    • 84876850544 scopus 로고    scopus 로고
    • Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
    • Eriksson SE, B?k T, Elgstr? E et al. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb. EJNMMI Res. 3, 23 (2013).
    • (2013) EJNMMI Res. , vol.3 , pp. 23
    • Eriksson, S.E.1    Bk, T.2    Elgstr, E.3
  • 91
    • 79959556136 scopus 로고    scopus 로고
    • Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides
    • Wilbur DS. Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. Curr. Radiopharm. 4, 214-247 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 214-247
    • Wilbur, D.S.1
  • 92
    • 84878194238 scopus 로고    scopus 로고
    • Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies
    • Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong HS. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. Nucl. Med. Biol. 40, 600-605 (2013).
    • (2013) Nucl. Med. Biol. , vol.40 , pp. 600-605
    • Kang, C.S.1    Song, H.A.2    Milenic, D.E.3    Baidoo, K.E.4    Brechbiel, M.W.5    Chong, H.S.6
  • 94
    • 0028070359 scopus 로고
    • Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac
    • Hartmann F, Horak EM, Garmestani K et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. 54, 4362-4370 (1994).
    • (1994) Cancer Res. , vol.54 , pp. 4362-4370
    • Hartmann, F.1    Horak, E.M.2    Garmestani, K.3
  • 97
    • 84859386203 scopus 로고    scopus 로고
    • 212Pbradioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease
    • Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pbradioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol. Cancer Ther. 11, 639-648 (2012).
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 639-648
    • Yong, K.J.1    Milenic, D.E.2    Baidoo, K.E.3    Brechbiel, M.W.4
  • 98
    • 34250217093 scopus 로고    scopus 로고
    • Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease
    • DOI 10.1158/1078-0432.CCR-06-2300
    • Milenic DE, Garmestani K, Brady ED et al. Potentiation of high-LET radiation by gemcitabine. targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13, 1926-1935 (2007). (Pubitemid 46957364)
    • (2007) Clinical Cancer Research , vol.13 , Issue.6 , pp. 1926-1935
    • Milenic, D.E.1    Garmestani, K.2    Brady, E.D.3    Albert, P.S.4    Abdulla, A.5    Flynn, J.6    Brechbiel, M.W.7
  • 99
    • 52649160241 scopus 로고    scopus 로고
    • Multimodality therapy potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease
    • Milenic DE, Garmestani K, Brady ED et al. Multimodality therapy. potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 14, 5108-5115 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 5108-5115
    • Milenic, D.E.1    Garmestani, K.2    Brady, E.D.3
  • 100
    • 84875214677 scopus 로고    scopus 로고
    • Sensitization of tumor to 212Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51
    • Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Sensitization of tumor to 212Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int. J. Radiat. Oncol. Biol. Phys. 85, 1119-1126 (2013).
    • (2013) Int. J. Radiat. Oncol. Biol. Phys. , vol.85 , pp. 1119-1126
    • Yong, K.J.1    Milenic, D.E.2    Baidoo, K.E.3    Brechbiel, M.W.4
  • 101
    • 84878550840 scopus 로고    scopus 로고
    • 212Pbradioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
    • Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pbradioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. Br. J. Cancer 108, 2013-2020 (2013).
    • (2013) Br. J. Cancer , vol.108 , pp. 2013-2020
    • Yong, K.J.1    Milenic, D.E.2    Baidoo, K.E.3    Brechbiel, M.W.4
  • 102
    • 84880785330 scopus 로고    scopus 로고
    • Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb
    • Boudousq V, Bobyk L, Busson M et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS ONE 8, e69613 (2013).
    • (2013) PLoS ONE , vol.8
    • Boudousq, V.1    Bobyk, L.2    Busson, M.3
  • 103
    • 16444385850 scopus 로고    scopus 로고
    • A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro
    • DOI 10.1089/cbr.2005.20.52
    • Nayak T, Norenberg J, Anderson T, Atcher R. A comparison of high-versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother. Radiopharm. 20, 52-57 (2005). (Pubitemid 40478522)
    • (2005) Cancer Biotherapy and Radiopharmaceuticals , vol.20 , Issue.1 , pp. 52-57
    • Nayak, T.1    Norenberg, J.2    Anderson, T.3    Atcher, R.4
  • 104
    • 84875792991 scopus 로고    scopus 로고
    • Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio-and chemoresistant non-Hodgkin lymphoma cells
    • Roscher M, Hormann I, Leib O et al. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio-and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 4, 218-230 (2013).
    • (2013) Oncotarget , vol.4 , pp. 218-230
    • Roscher, M.1    Hormann, I.2    Leib, O.3
  • 105
    • 84879320732 scopus 로고    scopus 로고
    • Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio-and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large
    • doi:10.1016/j.ejca.2013.04.008 Epub ahead of print
    • Friesen C, Roscher M, Hormann I et al. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio-and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur. J. Cancer doi:10.1016/j.ejca.2013. 04.008 (2013) (Epub ahead of print).
    • (2013) Eur. J. Cancer
    • Friesen, C.1    Roscher, M.2    Hormann, I.3
  • 106
    • 84866160432 scopus 로고    scopus 로고
    • Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells
    • Haro KJ, Scott AC, Scheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood 120, 2087-2097 (2012).
    • (2012) Blood , vol.120 , pp. 2087-2097
    • Haro, K.J.1    Scott, A.C.2    Scheinberg, D.A.3
  • 108
    • 33845316055 scopus 로고    scopus 로고
    • Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins
    • Dadachova E, Patel MC, Toussi S et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 3, e427 (2006).
    • (2006) PLoS Med. , vol.3
    • Dadachova, E.1    Patel, M.C.2    Toussi, S.3
  • 109
    • 84857952424 scopus 로고    scopus 로고
    • Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication
    • Dadachova E, Kitchen SG, Bristol G et al. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS ONE 7, e31866 (2012).
    • (2012) PLoS ONE , vol.7
    • Dadachova, E.1    Kitchen, S.G.2    Bristol, G.3
  • 111
    • 65649121945 scopus 로고    scopus 로고
    • Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells
    • Bryan RA, Jiang Z, Huang X et al. Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells. Antimicrob. Agents Chemother. 53, 1679-1682 (2009).
    • (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 1679-1682
    • Bryan, R.A.1    Jiang, Z.2    Huang, X.3
  • 112
    • 77954690760 scopus 로고    scopus 로고
    • Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection
    • Bryan RA, Jiang Z, Howell RC et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J. Infect. Dis. 202, 633-637 (2010).
    • (2010) J. Infect. Dis. , vol.202 , pp. 633-637
    • Bryan, R.A.1    Jiang, Z.2    Howell, R.C.3
  • 114
    • 84860586440 scopus 로고    scopus 로고
    • Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens
    • Bryan RA, Guimaraes AJ, Hopcraft S et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 173, 463-471 (2012).
    • (2012) Mycopathologia , vol.173 , pp. 463-471
    • Bryan, R.A.1    Guimaraes, A.J.2    Hopcraft, S.3
  • 116
    • 77953330556 scopus 로고    scopus 로고
    • Pilot study of a 213bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation
    • Nakamae H, Kerbauy FR, Wilbur DS et al. Pilot study of a 213bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation 89, 1336-1340 (2010).
    • (2010) Transplantation , vol.89 , pp. 1336-1340
    • Nakamae, H.1    Kerbauy, F.R.2    Wilbur, D.S.3
  • 117
    • 65549097348 scopus 로고    scopus 로고
    • Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211
    • Nakamae H, Wilbur DS, Hamlin DK et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 69, 2408-2415 (2009).
    • (2009) Cancer Res. , vol.69 , pp. 2408-2415
    • Nakamae, H.1    Wilbur, D.S.2    Hamlin, D.K.3
  • 118
    • 0038044865 scopus 로고    scopus 로고
    • Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation
    • Bethge WA, Wilbur DS, Storb R et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101, 5068-5075 (2003). (Pubitemid 36857775)
    • (2003) Blood , vol.101 , Issue.12 , pp. 5068-5075
    • Bethge, W.A.1    Wilbur, D.S.2    Storb, R.3    Hamlin, D.K.4    Santos, E.B.5    Brechbiel, M.W.6    Fisher, D.R.7    Sandmaier, B.M.8
  • 119
    • 79960684246 scopus 로고    scopus 로고
    • Anti-CD45 pretargeted radioimmunotherapy using bismuth-213 high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    • Pagel JM, Kenoyer AL, B?k T et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213. high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 118, 703-711 (2011).
    • (2011) Blood , vol.118 , pp. 703-711
    • Pagel, J.M.1    Kenoyer, A.L.2    Bk, T.3
  • 120
    • 78549263790 scopus 로고    scopus 로고
    • Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: A preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
    • Park SI, Shenoi J, Pagel JM et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116, 4231-4239 (2010).
    • (2010) Blood , vol.116 , pp. 4231-4239
    • Park, S.I.1    Shenoi, J.2    Pagel, J.M.3
  • 122
    • 84887362097 scopus 로고    scopus 로고
    • 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma
    • Ch?el M, Gouard S, Gaschet J et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J. Nucl. Med. 54, 1597-1604 (2013).
    • (2013) J. Nucl. Med. , vol.54 , pp. 1597-1604
    • Chel, M.1    Gouard, S.2    Gaschet, J.3
  • 124
    • 52649160241 scopus 로고    scopus 로고
    • Multimodality therapy potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease
    • Milenic DE, Garmestani K, Brady ED et al. Multimodality therapy. potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 14, 5108-5115 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , pp. 5108-5115
    • Milenic, D.E.1    Garmestani, K.2    Brady, E.D.3
  • 125
    • 76249102432 scopus 로고    scopus 로고
    • Improved efficacy of alpha-particletargeted radiation therapy: Dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72
    • Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particletargeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 116(4 Suppl.), 1059-1066 (2010).
    • (2010) Cancer , vol.116 , Issue.4 SUPPL. , pp. 1059-1066
    • Milenic, D.E.1    Brady, E.D.2    Garmestani, K.3    Albert, P.S.4    Abdulla, A.5    Brechbiel, M.W.6
  • 128
    • 70349639994 scopus 로고    scopus 로고
    • Treatment of diffusetype gastric cancer cells using 213Bi- radioimmunoconjugates in vitro and in vivo following intraperitoneal dissemination
    • Seidl C, Senekowitsch-Schmidtke R. Treatment of diffusetype gastric cancer cells using 213Bi-radioimmunoconjugates in vitro and in vivo following intraperitoneal dissemination. Curr. Radiopharm. 1, 215-224 (2008).
    • (2008) Curr. Radiopharm. , vol.1 , pp. 215-224
    • Seidl, C.1    Senekowitsch-Schmidtke, R.2
  • 133
    • 26444446027 scopus 로고    scopus 로고
    • 213Bi- conjugated monoclonal antibody
    • DOI 10.1158/1078-0432.CCR-1004-0017
    • Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin. Cancer Res. 11(19 Pt 2), 7070s-7074s (2005). (Pubitemid 41428706)
    • (2005) Clinical Cancer Research , vol.11 , Issue.19
    • Bloechl, S.1    Beck, R.2    Seidl, C.3    Morgenstern, A.4    Schwaiger, M.5    Senekowitsch-Schmidtke, R.6
  • 134
    • 84862613060 scopus 로고    scopus 로고
    • High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum
    • Rauch C, Seidl C, Schlapschy M et al. High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum. Nucl. Med. Biol. 39, 617-627 (2012).
    • (2012) Nucl. Med. Biol. , vol.39 , pp. 617-627
    • Rauch, C.1    Seidl, C.2    Schlapschy, M.3
  • 135
    • 79551513604 scopus 로고    scopus 로고
    • 177Luimmunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi
    • Seidl C, Z?kler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. 177Luimmunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi. Eur. J. Nucl. Med. Mol. Imaging 38, 312-322 (2011).
    • (2011) Eur. J. Nucl. Med. Mol. Imaging , vol.38 , pp. 312-322
    • Seidl, C.1    Zkler, C.2    Beck, R.3    Quintanilla-Martinez, L.4    Bruchertseifer, F.5    Senekowitsch-Schmidtke, R.6
  • 136
    • 34848840131 scopus 로고    scopus 로고
    • 213Bi-C- functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy
    • DOI 10.1158/1078-0432.CCR-07-1071
    • Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyldiethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin. Cancer Res. 13(18 Pt 2), 5604s-5612s (2007). (Pubitemid 47510394)
    • (2007) Clinical Cancer Research , vol.13 , Issue.18
    • Kelly, M.P.1    Lee, F.T.2    Tahtis, K.3    Smyth, F.E.4    Brechbiel, M.W.5    Scott, A.M.6
  • 138
    • 45549088490 scopus 로고    scopus 로고
    • 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model
    • Song H, Shahverdi K, Huso DL et al. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 68, 3873-3880 (2008).
    • (2008) Cancer Res. , vol.68 , pp. 3873-3880
    • Song, H.1    Shahverdi, K.2    Huso, D.L.3
  • 140
    • 61349165644 scopus 로고    scopus 로고
    • Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted alpha radioimmunoconjugates
    • Li Y, Song E, Abbas Rizvi SM et al. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Clin. Cancer Res. 15, 865-875 (2009).
    • (2009) Clin. Cancer Res. , vol.15 , pp. 865-875
    • Li, Y.1    Song, E.2    Abbas Rizvi, S.M.3
  • 141
    • 84861717772 scopus 로고    scopus 로고
    • Orthotopic administration of 213Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate
    • Rizvi S, Allen B, Lee C et al. Orthotopic administration of 213Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate. Immunotherapy 4, 549-554 (2012).
    • (2012) Immunotherapy , vol.4 , pp. 549-554
    • Rizvi, S.1    Allen, B.2    Lee, C.3
  • 143
    • 70349644860 scopus 로고    scopus 로고
    • Intravesical alpharadioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice
    • Pfost B, Seidl C, Autenrieth M et al. Intravesical alpharadioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J. Nucl. Med. 50, 1700-1708 (2009).
    • (2009) J. Nucl. Med. , vol.50 , pp. 1700-1708
    • Pfost, B.1    Seidl, C.2    Autenrieth, M.3
  • 146
    • 49749151055 scopus 로고    scopus 로고
    • Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and betaemitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
    • Dahle J, Bruland OS, Larsen RH. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and betaemitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. Int. J. Radiat. Oncol. Biol. Phys. 72, 186-192 (2008).
    • (2008) Int. J. Radiat. Oncol. Biol. Phys. , vol.72 , pp. 186-192
    • Dahle, J.1    Bruland, O.S.2    Larsen, R.H.3
  • 147
    • 72949096312 scopus 로고    scopus 로고
    • Assessment of long-term radiotoxicity after treatment with the lowdose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab
    • Dahle J, Jonasdottir TJ, Heyerdahl H et al. Assessment of long-term radiotoxicity after treatment with the lowdose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab. Eur. J. Nucl. Med. Mol. Imaging 37, 93-102 (2010).
    • (2010) Eur. J. Nucl. Med. Mol. Imaging , vol.37 , pp. 93-102
    • Dahle, J.1    Jonasdottir, T.J.2    Heyerdahl, H.3
  • 148
    • 84864531160 scopus 로고    scopus 로고
    • Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab
    • Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS ONE 7, e42345 (2012).
    • (2012) PLoS ONE , vol.7
    • Heyerdahl, H.1    Abbas, N.2    Brevik, E.M.3    Mollatt, C.4    Dahle, J.5
  • 149
    • 84875912243 scopus 로고    scopus 로고
    • Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab
    • Abbas N, Heyerdahl H, Bruland OS, Borreb? J, Nesland J, Dahle J. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab. EJNMMI Res. 1, 18 (2011).
    • (2011) EJNMMI Res. , vol.1 , Issue.18
    • Abbas, N.1    Heyerdahl, H.2    Bruland, O.S.3    Borreb, J.4    Nesland, J.5    Dahle, J.6
  • 150
    • 84891398251 scopus 로고    scopus 로고
    • Comparing high LET 227Th-and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts
    • Abbas N, Heyerdahl H, Bruland ?S, Brevik EM, Dahle J. Comparing high LET 227Th-and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. Curr. Radiopharm. 6, 78-86 (2013).
    • (2013) Curr. Radiopharm. , vol.6 , pp. 78-86
    • Abbas, N.1    Heyerdahl, H.2    Bruland, S.3    Brevik, E.M.4    Dahle, J.5
  • 151
    • 84891385840 scopus 로고    scopus 로고
    • Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice
    • Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland ?, Dahle J. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. Curr. Radiopharm. 6, 106-116 (2013).
    • (2013) Curr. Radiopharm. , vol.6 , pp. 106-116
    • Heyerdahl, H.1    Abbas, N.2    Sponheim, K.3    Mollatt, C.4    Bruland, D.J.5
  • 152
    • 84881375764 scopus 로고    scopus 로고
    • Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting 227Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts
    • Heyerdahl H,Brevik EM, Dahle J. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting 227Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys. 87, 153-159 (2013).
    • (2013) Int. J. Radiat. Oncol. Biol. Phys. , vol.87 , pp. 153-159
    • Heyerdahl, H.1    Brevik, E.M.2    Dahle, J.3
  • 153
    • 84863490194 scopus 로고    scopus 로고
    • Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
    • Abbas N, Bruland ?S, Brevik EM, Dahle J. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. Nucl. Med. Commun. 33, 838-847 (2012).
    • (2012) Nucl. Med. Commun. , vol.33 , pp. 838-847
    • Abbas, N.1    Bruland, S.2    Brevik, E.M.3    Dahle, J.4
  • 154
    • 24944554605 scopus 로고    scopus 로고
    • Immunotherapy for acute myeloid leukemia
    • Jurcic JG. Immunotherapy for acute myeloid leukemia. Curr. Oncol. Rep. 7, 339-346 (2005). (Pubitemid 41309549)
    • (2005) Current Oncology Reports , vol.7 , Issue.5 , pp. 339-346
    • Jurcic, J.G.1
  • 155
    • 37649010802 scopus 로고    scopus 로고
    • Clinical experience with alpha-particle emitting 211At treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    • Zalutsky MR, Reardon DA, Akabani G et al. Clinical experience with alpha-particle emitting 211At. treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49, 30-38 (2008).
    • (2008) J. Nucl. Med. , vol.49 , pp. 30-38
    • Zalutsky, M.R.1    Reardon, D.A.2    Akabani, G.3
  • 156
    • 67650088549 scopus 로고    scopus 로고
    • Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients pharmacokinetics and dosimetry of 211At-MX35 F(ab')2-a Phase i study
    • Andersson H, Cederkrantz E, B?k T et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients. pharmacokinetics and dosimetry of 211At-MX35 F(ab')2-a Phase I study. J. Nucl. Med. 50, 1153-2260 (2009).
    • (2009) J. Nucl. Med. , vol.50 , pp. 1153-2260
    • Andersson, H.1    Cederkrantz, E.2    Bk, T.3
  • 157
    • 84890532810 scopus 로고    scopus 로고
    • Pharmacokinetics and Imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients
    • Meredith RF, Torgue J, Azure MT et al. Pharmacokinetics and Imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother. Radiopharm. 29(1), 12-17 (2014).
    • (2014) Cancer Biother. Radiopharm. , vol.29 , Issue.1 , pp. 12-17
    • Meredith, R.F.1    Torgue, J.2    Azure, M.T.3
  • 159
    • 25144500525 scopus 로고    scopus 로고
    • Phase i clinical study on alpha-therapy for non Hodgkin lymphoma
    • D?seldorf, Germany, 28-29 June 2004 Morgenstern A (Ed.):Institute for Transuranium Elements, Karlsruhe, Germany, 11
    • Schmidt D, Neumann F, Antke C et al. Phase I clinical study on alpha-therapy for non Hodgkin lymphoma. In: Proceedings of the 4th alpha-Immunotherapy Symposium. D?seldorf, Germany, 28-29 June 2004; Morgenstern A (Ed.): Institute for Transuranium Elements, Karlsruhe, Germany, 11 (2004). http://itu.jrc.ec.europa.eu/index.php?id=205
    • (2004) Proceedings of the 4th Alpha-Immunotherapy Symposium
    • Schmidt, D.1    Neumann, F.2    Antke, C.3
  • 161
    • 78049456138 scopus 로고    scopus 로고
    • Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    • Rosenblat TL, McDevitt MR, Mulford DA et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16, 5303-5311 (2010).
    • (2010) Clin. Cancer Res. , vol.16 , pp. 5303-5311
    • Rosenblat, T.L.1    McDevitt, M.R.2    Mulford, D.A.3
  • 163
    • 80053000534 scopus 로고    scopus 로고
    • Analysis of patient survival in a Phase i trial of systemic targeted α-therapy for metastatic melanoma
    • Allen BJ, Singla AA, Rizvi SM et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy 3, 1041-1050 (2011).
    • (2011) Immunotherapy , vol.3 , pp. 1041-1050
    • Allen, B.J.1    Singla, A.A.2    Rizvi, S.M.3
  • 165
    • 79959441137 scopus 로고    scopus 로고
    • Modelling and dosimetry for alpha-particle therapy
    • Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr. Radiopharm. 4, 261-265 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 261-265
    • Sgouros, G.1    Hobbs, R.F.2    Song, H.3
  • 167
    • 79959437613 scopus 로고    scopus 로고
    • Alpha-particle microdosimetr
    • Chouin N, Bardies M. Alpha-particle microdosimetry. Curr. Radiopharm. 4, 266-280 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 266-280
    • Chouin, N.1    Bardies, M.2
  • 169
    • 66349137472 scopus 로고    scopus 로고
    • Treatment of peritoneal carcinomatosis by targeted delivery of the radiolabeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells
    • Drecoll E, Gaertner FC, Miederer M et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radiolabeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE 4, e5715 (2009).
    • (2009) PLoS ONE , vol.4
    • Drecoll, E.1    Gaertner, F.C.2    Miederer, M.3
  • 170
    • 84862557219 scopus 로고    scopus 로고
    • Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumourhoming peptides in a preclinical mouse model of peritoneal carcinomatosis
    • Essler M, G?tner FC, Neff F et al. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumourhoming peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur. J. Nucl. Med. Mol. Imaging 39, 602-612 (2012).
    • (2012) Eur. J. Nucl. Med. Mol. Imaging , vol.39 , pp. 602-612
    • Essler, M.1    Gtner, F.C.2    Neff, F.3
  • 171
    • 84869094925 scopus 로고    scopus 로고
    • Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest
    • Vallon M, Seidl C, Blechert B et al. Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest. Eur. J. Nucl. Med. Mol. Imaging 39, 1886-1897 (2012).
    • (2012) Eur. J. Nucl. Med. Mol. Imaging , vol.39 , pp. 1886-1897
    • Vallon, M.1    Seidl, C.2    Blechert, B.3
  • 173
    • 77954952365 scopus 로고    scopus 로고
    • Targeted alpharadionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: A pilot trial
    • Cordier D, Forrer F, Bruchertseifer F et al. Targeted alpharadionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2) 11]-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging 37, 1335-1344 (2010).
    • (2010) Eur. J. Nucl. Med. Mol. Imaging , vol.37 , pp. 1335-1344
    • Cordier, D.1    Forrer, F.2    Bruchertseifer, F.3
  • 174
    • 79551553871 scopus 로고    scopus 로고
    • Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model 213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
    • Wild D, Frischknecht M, Zhang H et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model 213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 71, 1009-1018 (2011).
    • (2011) Cancer Res. , vol.71 , pp. 1009-1018
    • Wild, D.1    Frischknecht, M.2    Zhang, H.3
  • 176
    • 84856212043 scopus 로고    scopus 로고
    • Pretargeted radioimmunotherapy of colorectal cancer metastases models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide
    • Frampas E, Maurel C, Remaud-Le Sa? P et al. Pretargeted radioimmunotherapy of colorectal cancer metastases. models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur. J. Nucl. Med. Mol. Imaging 38, 2153-2164 (2011).
    • (2011) Eur. J. Nucl. Med. Mol. Imaging , vol.38 , pp. 2153-2164
    • Frampas, E.1    Maurel, C.2    Remaud-Le Sa, P.3
  • 177
    • 79959426898 scopus 로고    scopus 로고
    • Pretargeted radioimmunotherapy with α-particle emitting radionuclides
    • Lindegren S, Frost SH. Pretargeted radioimmunotherapy with α-particle emitting radionuclides. Curr. Radiopharm. 4, 248-260 (2011).
    • (2011) Curr. Radiopharm. , vol.4 , pp. 248-260
    • Lindegren, S.1    Frost, S.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.